共 54 条
[1]
Ackerman, Taylor, Olsen, Et al., Vancomycin serum protein binding determination by ultra-filtration, DICPAnn. Pharmacother., 22, (1988)
[2]
Anne, Hu, Chan, Et al., Potential problem with fluorescence polarization immunoassay cross-reactivity to vancomycin degradation product CDP-1: its detection in sera of renally impaired patients, Ther. Drug Monit., 11, (1989)
[3]
Bailie, Neal, Vancomycin ototoxicity and nephrotoxicity, A review, 3, (1988)
[4]
Bellomo, Emest, Parkin, Clearance of vancomycin during continuous arteriovenous hemodiafiltration, Crit. Care Med., 18, (1990)
[5]
Blevins, Halstenson, Salem, Et al., Pharmacokinetics of vancomycin in patients undergoing continuous ambulatory peritoneal dialysis, Antimicrob. Agents Chemother., 25, (1984)
[6]
Blouin, Bauer, Miller, Et al., Vancomycin pharmacokinetics in normal and morbidly obese subjects, Antimicrob. Agents Chemother., 21, (1982)
[7]
Boeckh, Lode, Bomer, Et al., Pharmacokinetics and serum bactericidal activity of vancomycin alone and in combination with ceftazidime in healthy volunteers, Antimicrob. Agents Chemother., 32, (1988)
[8]
Brater, Bawdon, Anderson, Et al., Vancomycin elimination in patients with bum injury, Clin. Pharmacol. Ther., 39, (1986)
[9]
Brown, Altmann, Cunningham, Et al., Pharmacokinetics of once daily intra-peritoneal aztreonam and vancomycin in the treatment of CAPD peritonitis, J. Antimicrob. Chemother., 25, (1990)
[10]
Brown, Ho, Fong, Et al., Effects of hepatic function on vancomycin clinical pharmacology, Antimicrob. Agents Chemother., 23, (1983)